Compare Krispy Kreme Inc (DNUT) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs DexCom, Inc. — how do they compare? Krispy Kreme Inc trades at $2.96 (market cap $521.37M), while DexCom, Inc. trades at $84.03 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 61.1× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and DexCom, Inc. for 62 Days on average.
| DNUT | DXCM | |
|---|---|---|
Market Cap | $521.37M | $31.86B |
Volume | 2,293,015 | 3,607,070 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $92.34 |
52-Week Low | $2.87 | $54.84 |
Typical Hold Time | 45 Days | 62 Days |
Enterprise Value | $1.76B | $31.32B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% today, amid bearish technical signals and negative profitability. The company reported a significant net loss of $515.77M in 2025 despite $1.52B revenue, with negative margins and declining cash flow from operations. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, creating investor uncertainty alongside seasonal product launches.
The outlook remains challenged by persistent losses and high debt levels, though analyst consensus leans bullish with 50% buy ratings. Key risks include legal overhangs, competitive pressure, and execution on profitability. Valuation metrics show mixed signals with low P/S but negative earnings, requiring careful monitoring of turnaround efforts and legal developments.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
